NasdaqGS:INCY

Stock Analysis Report

Executive Summary

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Incyte's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.08%

NasdaqGS:INCY

-0.5%

US Biotechs

-0.02%

US Market


1 Year Return

16.8%

NasdaqGS:INCY

-11.3%

US Biotechs

1.6%

US Market

INCY outperformed the Biotechs industry which returned -10.2% over the past year.

INCY outperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

INCYIndustryMarket
7 Day0.08%-0.5%-0.02%
30 Day-7.1%-2.1%2.7%
90 Day-9.3%-1.9%1.4%
1 Year16.8%16.8%-10.6%-11.3%3.8%1.6%
3 Year-9.4%-9.4%4.6%1.1%45.2%35.8%
5 Year59.2%59.2%1.9%-3.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Incyte's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Incyte undervalued based on future cash flows and its price relative to the stock market?

28%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Incyte's share price is below the future cash flow value, and at a moderate discount (> 20%).

Incyte's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Incyte is overvalued based on earnings compared to the US Biotechs industry average.

Incyte is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Incyte is poor value based on expected growth next year.


Price Based on Value of Assets

Incyte is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Incyte expected to perform in the next 1 to 3 years based on estimates from 20 analysts?

35.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Incyte's revenue is expected to grow by 16% yearly, however this is not considered high growth (20% yearly).

Incyte's earnings are expected to grow significantly at over 20% yearly.

Incyte's revenue growth is expected to exceed the United States of America market average.

Incyte's earnings growth is expected to exceed the United States of America market average.

Incyte's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Incyte is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Incyte performed over the past 5 years?

18.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Incyte's year on year earnings growth rate has been positive over the past 5 years.

Incyte has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Incyte has become profitable in the last year making it difficult to compare the US Biotechs industry average.


Return on Equity

Incyte has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Incyte used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Incyte's use of capital has not improved over the past 3 years (Return on Capital Employed).


Next Steps

Financial Health

How is Incyte's financial position?


Financial Position Analysis

Incyte is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Incyte's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Incyte's level of debt (0.8%) compared to net worth is satisfactory (less than 40%).

Incyte had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.

Debt is well covered by operating cash flow (3312.1%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 220.2x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 115.3x debt.


Next Steps

Dividend

What is Incyte's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Incyte's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Incyte's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Incyte has not reported any payouts.

Unable to verify if Incyte's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Incyte has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Incyte's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Incyte's salary, the management and board of directors tenure and is there insider trading?

3.7yrs

Average management tenure


CEO

Hervé Hoppenot (59yo)

5.7yrs

Tenure

US$9,314,189

Compensation

Mr. Hervé Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and President since January 13, 2014. Mr. Hoppenot served as the Chief Commerci ...


CEO Compensation Analysis

Hervé's remuneration is about average for companies of similar size in United States of America.

Hervé's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.7yrs

Average Tenure

52yo

Average Age

The tenure for the Incyte management team is about average.


Board Age and Tenure

5.2yrs

Average Tenure

61.5yo

Average Age

The tenure for the Incyte board of directors is about average.


Insider Trading

Incyte individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$146,65405 Aug 19
Jean-Jacques Bienaimé
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,724
Max PriceUS$85.16
SellUS$76,63418 Jul 19
Barry Flannelly
EntityIndividual
Shares959
Max PriceUS$79.91
BuyUS$68,76509 Nov 18
Jean-Jacques Bienaimé
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$68.91

Ownership Breakdown


Management Team

  • Pamela Murphy (68yo)

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Mike Booth (48yo)

    Divisional Vice President of Investor Relations & Corporate Social Responsibility

    • Tenure: 5.5yrs
  • Christiana Stamoulis (48yo)

    Executive VP & CFO

    • Tenure: 0.6yrs
  • Wenqing Yao (56yo)

    Executive VP & Head of Discovery Chemistry

    • Tenure: 4.9yrs
    • Compensation: US$6.54m
  • Hervé Hoppenot (59yo)

    Chairman

    • Tenure: 5.7yrs
    • Compensation: US$9.31m
  • Steven Stein (52yo)

    Executive VP & Chief Medical Officer

    • Tenure: 4.5yrs
    • Compensation: US$6.61m
  • Michael Morrissey

    Executive VP & Head of Global Technical Operations

    • Tenure: 3.7yrs
  • Vijay Iyengar (46yo)

    Executive VP of Global Strategy & Corporate Development

    • Tenure: 3.3yrs
  • Maria Pasquale

    Executive VP & General Counsel

    • Tenure: 1.4yrs
    • Compensation: US$3.62m
  • Dashyant Dhanak

    Executive VP & Chief Scientific Officer

    • Tenure: 0.8yrs

Board Members

  • Paul Brooke (73yo)

    Independent Director

    • Tenure: 18.7yrs
    • Compensation: US$522.37k
  • Jean-Jacques Bienaimé (66yo)

    Independent Director

    • Tenure: 4.7yrs
    • Compensation: US$485.37k
  • Jim Baker (52yo)

    • Tenure: 5.7yrs
    • Compensation: US$503.37k
  • Jackie Fouse (58yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$477.37k
  • Paul Friedman (76yo)

    Independent Director

    • Tenure: 17.8yrs
    • Compensation: US$477.37k
  • Wendy Dixon (64yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$492.37k
  • Paul Clancy (57yo)

    Independent Director

    • Tenure: 4.7yrs
    • Compensation: US$497.37k
  • Hervé Hoppenot (59yo)

    Chairman

    • Tenure: 5.7yrs
    • Compensation: US$9.31m

Company Information

Incyte Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Incyte Corporation
  • Ticker: INCY
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$16.891b
  • Shares outstanding: 215.07m
  • Website: https://www.incyte.com

Number of Employees


Location

  • Incyte Corporation
  • 1801 Augustine Cut-Off
  • Wilmington
  • Delaware
  • 19803
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INCYNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDNov 1993
ICYDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 1993
INCYWBAG (Wiener Boerse AG)YesCommon SharesATEURNov 1993
0J9PLSE (London Stock Exchange)YesCommon SharesGBUSDNov 1993
INCY *BMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNNov 1993

Biography

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatme ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 23:36
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.